About Francisco

Francisco Averhoff, MD, MPH, CAPT, USPHS, serves in his current position as the Associate Director for Global Health in the Division of Viral Hepatitis (DVH) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. In this position he is responsible for developing and implementing the DVH global strategy for viral hepatitis research and control.

Dr. Averhoff did his undergraduate studies at the University of California at Davis, received his Medical Degree at the University of California at Irvine, and Master of Public Health degree at Johns Hopkins University. He is Board Certified in both Family Medicine and Preventive Medicine.

Prior to joining the CDC, he served as an instructor of Family Medicine, worked as a volunteer physician in rural Nigeria, and worked for the World Health Organization (WHO) on polio eradication in Latin America and from WHO Headquarters in Geneva. He joined the Public Health Service (PHS) and the CDC in 1992 as an EIS Officer assigned to the Hepatitis Branch through 1994. He served with the National Immunization Program from 1994 - 2005, and in Indonesia as a CDC assignee to the World Health Organization (WHO) during 2001 - 2003, and was the Branch Chief at Quarantine and Border Health Services Branch (QBHSB) during 2006 - 2009 prior to returning to DVH in 2010.

Dr. Averhoff has conducted research and practiced public health on a variety of subjects since joining CDC including viral hepatitis epidemiology and prevention, adolescent immunization, smallpox, measles, mumps, rubella, polio, influenza and varicella epidemiology and immunization, and the 2009 pandemic response. Dr. Averhoff has published extensively in the peer reviewed literature and authored book chapters. He continues to practice medicine and sees patients at the Liver Clinic and International Medical Clinic at Grady Hospital in Atlanta.

This speaker will be presenting at the following session(s)

  • Strategic direction 5: Innovation for acceleration

    Plenary

    Day: Friday 3

    Time: 14:00

    Innovation can help drive towards the overall objective of hepatitis elimination in a wide range of settings. This innovation session will highlight innovations related to hepatitis B and C products, programs and policies.

    Presentations:

    • Introduction and importance of innovation.
    • Innovation plenary.
    • Product innovation.
      Dr Francesco Marinucci, Foundation for Innovative New Diagnostics
    • Program innovation.
      Dr Joseph Tucker, University of North Carolina
    • Policy innovation.
      Dr Bobby John, Global Health Advocates
    • Wrap-up panel.

    Session objectives:

    • Learn the importance of innovation in developing hepatitis B and C control programs, policies and products.
    • Understand new products for hepatitis B and C control that could accelerate detection, treatment and retention.
    • Discuss new policies for expanding access to hepatitis B and C testing, treatment and prevention strategies.
    • Learn about new programs and public health interventions to optimize comprehensive hepatitis care.